Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study

Katarzyna Gustaw‐Rothenberg; Sandra L. Siedlak; David Bonda; Alan J. Lerner; Massimo Tabaton; George Perry; Mark A. Smith

doi:10.1016/j.exger.2009.10.003

Related publications

Article2009

P3‐073: Dissociated A<i>β</i> antibody level in newly diagnosed Alzheimer's disease: A population‐based study

Katarzyna Gustaw‐Rothenberg, Sandra L. Siedlak, Hyoung‐gon Lee, Rudy J. Castellani, Xiongwei Zhu, George Perry, Robert B. Petersen, Robert P. Friedland, Alan J. Lerner, Mark A. Smith

Article2016

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Anna M. Pietroboni, Francesca Schiano di Cola, Marta Scarioni, Chiara Fenoglio, Barbara Spanò, Andrea Arighi, Sara Cioffi, Emanuela Oldoni, Milena De Riz, Paola Basilico, Alberto Calvi, Giorgio Fumagalli, Fabio Triulzi, Daniela Galimberti, Marco Bozzali, Elio Scarpini

Article2021

The Amyloid-β Pathway in Alzheimer’s Disease

Harald Hampel, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo

Article2009

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

Rudy J. Castellani, Hyoung‐gon Lee, Sandra L. Siedlak, Akihiko Nunomura, Takaaki Hayashi, Masao Nakamura, Xiongwei Zhu, George Perry, Mark A. Smith

Article2005

Role of Amyloid‐β in Alzheimer's Disease

Mark A. Smith, George Perry